• No results found

[PDF] Top 20 Developments in managing severe chronic pain: role of oxycodone–naloxone extended release

Has 10000 "Developments in managing severe chronic pain: role of oxycodone–naloxone extended release" found on our website. Below are the top 20 most common "Developments in managing severe chronic pain: role of oxycodone–naloxone extended release".

Developments in managing severe chronic pain: role of oxycodone–naloxone extended release

Developments in managing severe chronic pain: role of oxycodone–naloxone extended release

... to-severe pain in a wide range of ...efficacy, chronic management with opioids is often compromised by adverse effects which include nausea, sedation, euphoria/dysphoria, itching, and what is called ... See full document

6

Long-term efficacy and safety of oxycodone–naloxone prolonged release in geriatric patients with moderate-to-severe chronic noncancer pain: a 52-week open-label extension phase study

Long-term efficacy and safety of oxycodone–naloxone prolonged release in geriatric patients with moderate-to-severe chronic noncancer pain: a 52-week open-label extension phase study

... OXN-PR. The initial PI was halved at T4 and further reduced at T52. It should not be taken for granted that the efficacy was maintained for such an extended time. Opioid therapy often runs into tolerance, whose ... See full document

9

<p>Healthcare Costs And Resource Utilization In Chronic Pain Patients Treated With Extended-Release Formulations Of Tapentadol, Oxycodone, Or Morphine Stratified By Type Of Pain: A Retrospective Claims Analysis, 2012–2016</p>

<p>Healthcare Costs And Resource Utilization In Chronic Pain Patients Treated With Extended-Release Formulations Of Tapentadol, Oxycodone, Or Morphine Stratified By Type Of Pain: A Retrospective Claims Analysis, 2012&ndash;2016</p>

... with oxycodone among IR formulations was also ...convenient pain relief for a substan- tially higher number of patients, with a lower rate of common opioid-related adverse events, at a marginally higher ... See full document

12

A comparison  between the administration of oral prolonged-release oxycodone-naloxone and transdermal fentanyl in patients with moderate-to-severe cancer pain: a propensity score analysis

A comparison between the administration of oral prolonged-release oxycodone-naloxone and transdermal fentanyl in patients with moderate-to-severe cancer pain: a propensity score analysis

... Table 1 shows the baseline clinical characteristics accord- ing to the different treatments. The most common sites of can- cer were the respiratory, digestive, and genitourinary systems. Over 80% of patients in each ... See full document

11

Quality of life under oxycodone/naloxone, oxycodone, or morphine treatment for chronic low back pain in routine clinical practice

Quality of life under oxycodone/naloxone, oxycodone, or morphine treatment for chronic low back pain in routine clinical practice

... The participating physicians collected data at baseline, week 4, and week 12 (end of observation) using a web application providing standardized case report forms. They rated quality of life with an eleven-point ... See full document

13

Restless legs syndrome: a new entity of neuropathic pain? Treatment with prolonged release oxycodone/naloxone combination

Restless legs syndrome: a new entity of neuropathic pain? Treatment with prolonged release oxycodone/naloxone combination

... prolonged-release oxycodonenaloxone was efficacious for short-term treatment of patients with severe RLS inadequately controlled with previous ... See full document

5

A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain

A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain

... The OXN2001 trial (ClinicalTrials.gov identifier NCT00513656) 32 was a 4-week, international, multicen- tre, randomized, double-blind, active-controlled, double-dummy, parallel-group, Phase II study, designed to evaluate ... See full document

11

Efficacy and safety of controlled-release oxycodone/naloxone versus controlled-release oxycodone in Korean patients with cancer-related pain: a randomized controlled trial

Efficacy and safety of controlled-release oxycodone/naloxone versus controlled-release oxycodone in Korean patients with cancer-related pain: a randomized controlled trial

... to severe cancer‑related pain [numeric rating scale (NRS) pain score ≥ 4] from seven Korean oncology/hematology ...NRS pain score from baseline to week 4, with non‑inferiority margin of − ... See full document

9

Extended-release morphine sulfate in treatment of severe acute and chronic pain

Extended-release morphine sulfate in treatment of severe acute and chronic pain

... Notes: Copyright © 2008, American Society of interventional Pain Physicians. All rights reserved. Reproduced with permission from Trescot A, Datta S, Lee M, Hansen H. Opioid pharmacology. Pain Physician. ... See full document

10

Effectiveness and safety of oxycodone/naloxone in the management of chronic pain in patients with systemic sclerosis with recurrent digital ulcers: two case reports

Effectiveness and safety of oxycodone/naloxone in the management of chronic pain in patients with systemic sclerosis with recurrent digital ulcers: two case reports

... a severe and frequent clinical feature of patients with systemic sclerosis ...cause severe pain and often lead to impairment of patient’s functional activities and health-related quality of ...to ... See full document

5

Cancer pain therapy with a fixed combination of prolonged-release oxycodone/naloxone: results from a non-interventional study

Cancer pain therapy with a fixed combination of prolonged-release oxycodone/naloxone: results from a non-interventional study

... good.” Oxycodone, in particular, showed good effectiveness; patients who had received this analgesic had the lowest values across all items of pain intensity, as reported at ...more severe and more ... See full document

13

Analgesic efficacy, safety, and tolerability of a long-acting abuse-deterrent formulation of oxycodone for moderate-to-severe chronic low back pain in subjects successfully switched from immediate-release oxycodone

Analgesic efficacy, safety, and tolerability of a long-acting abuse-deterrent formulation of oxycodone for moderate-to-severe chronic low back pain in subjects successfully switched from immediate-release oxycodone

... average pain intensity measured by the change in PI-NRS score from Randomization Baseline to Week 12 of the Double-blind Maintenance ...in pain intensity score from Randomization Baseline to all weeks, ... See full document

9

Is oxycodone/naloxone effective and safe in managing chronic pain of a fragile elderly patient with multiple skin ulcers of the lower limbs? A&amp;nbsp;case report&lt;div&gt;&amp;nbsp;&lt;/div&gt;

Is oxycodone/naloxone effective and safe in managing chronic pain of a fragile elderly patient with multiple skin ulcers of the lower limbs? A&nbsp;case report<div>&nbsp;</div>

... concomitant chronic diseases typically occur in advanced age, thereby predisposing to these painful ...Wound-related pain is often associated with skin ulcers and negatively impacts both the patient’s ... See full document

5

Development of opioid-induced constipation: post hoc analysis of data from a 12-week prospective, open-label, blinded-endpoint streamlined study in low-back pain patients treated with prolonged-release WHO step III opioids

Development of opioid-induced constipation: post hoc analysis of data from a 12-week prospective, open-label, blinded-endpoint streamlined study in low-back pain patients treated with prolonged-release WHO step III opioids

... had severe respiratory depression, chronic obstructive airway disease, pulmonary hypertension, severe bronchial asthma, paralytic ileus, moderate to severe hepatic impairment and/or renal ... See full document

17

Switching to low-dose oral prolonged-release oxycodone/naloxone from WHO-Step I drugs in elderly patients with chronic pain at high risk of early opioid discontinuation

Switching to low-dose oral prolonged-release oxycodone/naloxone from WHO-Step I drugs in elderly patients with chronic pain at high risk of early opioid discontinuation

... of chronic moderate to severe pain in subjects who have never been treated before with opioid ...with severe pain and bowel dysfunction, ...of pain and improvement, or no ... See full document

9

Efficacy and tolerability of low-dose oral prolonged-release oxycodone/naloxone for chronic nononcological pain in older patients

Efficacy and tolerability of low-dose oral prolonged-release oxycodone/naloxone for chronic nononcological pain in older patients

... from chronic pain of moderate-to-severe intensity suggest that low doses of OXN-PR provided effective anal- gesia and were generally well tolerated with no occurrence of constipation and other ... See full document

11

&lt;p&gt;Tapentadol for neuropathic pain: a review of clinical studies&lt;/p&gt;

<p>Tapentadol for neuropathic pain: a review of clinical studies</p>

... with chronic low back pain (CLBP) being the leading condition of disability, chronic neck pain (CNP) ranking fourth and other musculoskeletal conditions and osteoarthritis ranking tenth and ... See full document

15

Tapentadol extended release for the management of chronic neck pain

Tapentadol extended release for the management of chronic neck pain

... Pain-free active neck ROM significantly improved in all three planes of motion over the course of the study (P< 0.01). Pre/posttreatment effect sizes were large for all the outcomes (Table 2). Percentage of ... See full document

11

Tapentadol extended release in the management of peripheral diabetic neuropathic pain

Tapentadol extended release in the management of peripheral diabetic neuropathic pain

... of chronic pain conditions, including back pain, cancer-related pain, and arthritic ...tapentadol extended release has been demonstrated to be effective in the management of ... See full document

11

&lt;p&gt;Tapentadol: an effective option for the treatment of back pain&lt;/p&gt;

<p>Tapentadol: an effective option for the treatment of back pain</p>

... Back pain, including low back pain and neck pain, is the leading cause of disability ...of pain is challenging to treat, since it presents both a nociceptive and a neuropathic ...of ... See full document

8

Show all 10000 documents...